Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
- Written by PR Newswire
![]() |
- Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026
- Appoints US-based Chief Commercial Officer, Andrew Udell
- Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media.
SYDNEY, Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the first...